Aktienanalyse zu Silence Therapeutics PLC (SLN)SLNSilence Therapeutics PLC

Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Silence Therapeutics PLC is not a good buy right now due to its current price of $8.68 being significantly below analyst targets and a very low RSI of 24.913 indicating oversold conditions. The company has shown a substantial year-to-date change of +41.14%, but recent performance has been poor with a 5-day change of -11.97%. The main risk is the high net loss of $12.2 million reported in Q2 2026, which raises concerns about financial stability.